Smart City Dimensions and Associated Risks: Review of literature

Countries have been working on implementing smart city concepts in different regions. The need for the use of information and communication technology in various forms is needed in such cities. There are different dimensions that are to be considered for smart city planning and implementation. This complexity of the dimension, the use of technology, and their integration bring the risk perspectives into the implementation of the smart city concept. If such risks are not adequately understood and addressed, they can create issues in terms of privacy and security and, therefore, the functioning of smart cities. In this review, the identification of dimensions, smart city assessment tools, the available technologies, and the technical and non-technical risk parameters related to smart cities implementation are discussed. The current methods of risk assessment and the possible enhancements are highlighted. The findings of the literature review illustrate that not all smart cities adapt all of the smart city dimensions. The dominant technology used in smart cities' applications is found to be the Internet of Things, Artificial Intelligence, and blockchain. The paper also provides some research directions for the design, implementation, and operation of smart cities. 2021 The Author(s)N\A, There is no funding recived to complete this review paper.Scopus2-s2.0-8511950365

A fully automated cell segmentation and morphometric parameter system for quantifying corneal endothelial cell morphology

YesBackground and Objective Corneal endothelial cell abnormalities may be associated with a number of corneal and systemic diseases. Damage to the endothelial cells can significantly affect corneal transparency by altering hydration of the corneal stroma, which can lead to irreversible endothelial cell pathology requiring corneal transplantation. To date, quantitative analysis of endothelial cell abnormalities has been manually performed by ophthalmologists using time consuming and highly subjective semi-automatic tools, which require an operator interaction. We developed and applied a fully-automated and real-time system, termed the Corneal Endothelium Analysis System (CEAS) for the segmentation and computation of endothelial cells in images of the human cornea obtained by in vivo corneal confocal microscopy. Methods First, a Fast Fourier Transform (FFT) Band-pass filter is applied to reduce noise and enhance the image quality to make the cells more visible. Secondly, endothelial cell boundaries are detected using watershed transformations and Voronoi tessellations to accurately quantify the morphological parameters of the human corneal endothelial cells. The performance of the automated segmentation system was tested against manually traced ground-truth images based on a database consisting of 40 corneal confocal endothelial cell images in terms of segmentation accuracy and obtained clinical features. In addition, the robustness and efficiency of the proposed CEAS system were compared with manually obtained cell densities using a separate database of 40 images from controls (n = 11), obese subjects (n = 16) and patients with diabetes (n = 13). Results The Pearson correlation coefficient between automated and manual endothelial cell densities is 0.9 (p < 0.0001) and a Bland–Altman plot shows that 95% of the data are between the 2SD agreement lines. Conclusions We demonstrate the effectiveness and robustness of the CEAS system, and the possibility of utilizing it in a real world clinical setting to enable rapid diagnosis and for patient follow-up, with an execution time of only 6 seconds per image

Association between Serum Vitamin B12 Concentration and Obesity Among Adults in The Ksa

Objective: To investigate the relationship between serum vitamin B12 levels and weight among the adult population in KSA. Methods: This research will employ a cross-sectional study design to investigate the association between serum vitamin B12 concentration and obesity among adults in the Kingdom of Saudi Arabia (KSA). Cross-sectional studies are suitable for examining relationships between variables within a specific population at a single point in time. The target population for this study includes all adult residents of the KSA aged 18 years and older. Results: The study included 869 participants. The most frequent weight among them was 51-65 kg (n= 255, 29.3%), followed by 66 -75 kg (n= 214, 24.6%). The most frequent height among study participants was 161-170 cm (n= 324, 37.3%) followed by 151-160 cm (n= 266, 30.6%). The most frequent body mass index (BMI) value among study participants was Normal 18.5-24.9 kg/m2 (n= 344, 39.6%), followed by overweight 25-29.9 kg/m2 (n= 281, 32.3%).  Vitamin B12 varied among study participants, with most of them having a normal range (n= 319, 36.7%) followed by a low range (n= 117, 13.5%) and the least common high range (n= 23, 2.6%). On the other hand, among 410 participants, 47.2% did not know their vitamin B12 value. Wech may indicate a lack of knowledge about the topic. Figure 4 shows the vitamin B12 levels among study participants. Conclusion: Study results showed that most of the study participants do not know their vitamin B12 level and need to increase awareness, followed by those who have a normal vitamin B12 level. The most common BMI was the normal level. There was a relationship between vitamin B12 levels and obesity.

Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK ‘Alert Level 4’ phase of the B-MaP-C study

Abstract: Background: The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions. Methods: This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting. Findings: Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey. Conclusions: The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

Smart City Perspectives in the Context of Qatar

The smart city concept is being implemented in different countries. In order to make such a concept successful, countries need to invest heavily in information and communication technology and provide opportunity to utilize them for creating economic and social value. As the access to such technology, the funds required for investments, and the manpower needed to take such a concept forward, the right use of such technology becomes challenging. The challenge requires and understanding of dimensions and the risks associated with the investment and use of information and communication technology. The complexity of the technology and its integration also brings in to risks associate with it. When risks are not adequately understood and addressed, they may cause security and privacy issues, thereby affecting the very concept of smart city. This paper focuses on identifying smart city dimensions, and the technical and non-technical risks. Qatar's smart city project and the risks related to the information and communication technology applications used at the project are presented. 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.Scopus2-s2.0-8511347488

Risk analysis with the dempster-shafer theory for smart city planning: The case of qatar

Smart cities support the enhancement of the quality of life of their residents, for which the use of a robust integrated platform of information and communication technology is required. However, not all cities have similar technology infrastructure and a similar understanding of the quality of life. Therefore, holistic planning, resource support, security, continuous updates, and dynamic operational enhancements should be considered while planning smart cities. However, a smart city could be vulnerable to security threats and a loss of personal or classified information due to the complexity of technology integration. Therefore, understanding and assessing different risks and embedding risk management mechanisms would be required to minimize vulnerability exposure in smart cities. This paper proposes a risk assessment method using the Dempster-Shafer theory for smart city planning. The Dempster-Shafer theory is used here to analyze the risks perceptions of experts. The principal component analysis method is used to analyze the data obtained from risk assessment. The application of this method is determined through a smart city test case in Qatar. 2021 by the authors. Licensee MDPI, Basel, Switzerland.Scopus2-s2.0-8512078155

Enabling Open Innovation in Digital Startups through the Incubation Program-A Case of Qatar

Researchers have studied open innovation by focusing primarily on big organizations. With digitization, the adoption of open innovation has become widespread, as there is broader access to cheaper and better information and communication technology. Private or public companies will also support individuals, or a group of individuals, to promote an innovative economy. Some countries also provide incubation opportunities and technical and financial support to encourage digital startups. This paper presents insights on the incubation program organized by one of the prominent centers in Qatar that incubate interested potential entrepreneurs to utilize open innovation for digital startups. The paper uses a qualitative analysis method on the data obtained from the interviews with the trainers (staff) of the center and the entrepreneurs who went through the incubation process. Four hypotheses were developed to understand various aspects of open innovation, the collaboration of startups, and the role of the incubation center. A nonparametric statistical test was used to assess the validity of the hypotheses. The results show that incubation and open innovation can contribute to digital startups. The paper concludes with suggested enhancements for incubation. This paper complements the literature by providing a study of open innovation in digital startups and introducing future research in this field. 2022 by the authors. Licensee MDPI, Basel, Switzerland.Government financial support for startupsScopus2-s2.0-8513154734